{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:43:47Z","timestamp":1789559027853,"version":"build-2803163510"},"reference-count":12,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,4,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The Follicular Lymphoma (FL) International Prognostic Index (FLIPI) and FLIPI-2 are well-described clinical risk models. Age &amp;gt;60 years at diagnosis is a risk factor in both scores. Recently, we showed that older age is not associated with higher risk of disease progression or inferior treatment efficacy. Instead, shorter survival of older patients results mainly from an increased risk of nonrelapse deaths. This questions the value of age as a meaningful component of scores intended to predict disease-specific survival. The newly proposed PRIMA-prognostic index (PRIMA-PI) only includes \u03b22-microglobulin levels and bone marrow infiltration as risk factors. Here, we independently validate the PRIMA-PI in a clinical trial cohort of 475 patients with advanced FL who uniformly received cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone, and rituximab (R-CHOP) as frontline therapy. The PRIMA-PI separated 3 similar sized risk cohorts with 5-year progression-free survival (PFS) rates of 74%, 59%, and 39%, respectively (P &amp;lt; .0001). Furthermore, we compare the PRIMA-PI with the FLIPI and FLIPI-2. We demonstrate that the PRIMA-PI has the highest specificity to identify high-risk patients (80% for 5-year PFS) because of its superior risk stratification in patients &amp;gt;60 years (73% vs 33% [FLIPI] and 47% [FLIPI-2] for 5-year PFS). Thus, the PRIMA-PI is a promising clinical tool to stringently identify patients at highest risk of poor outcome after frontline R-CHOP for advanced FL, and is particularly useful in patients with older age. Further validation in non\u2013R-CHOP treated cohorts is needed.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019032136","type":"journal-article","created":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T20:55:40Z","timestamp":1554238540000},"page":"1033-1038","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":23,"title":["Impact of age on clinical risk scores in follicular lymphoma"],"prefix":"10.1182","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6825-702X","authenticated-orcid":false,"given":"Stefan","family":"Alig","sequence":"first","affiliation":[{"name":"Department of Medicine III, University Hospital, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vindi","family":"Jurinovic","sequence":"additional","affiliation":[{"name":"Department of Medicine III, University Hospital, and"},{"name":"Institute for Medical Information Processing, Biometry and Epidemiology, Ludwig-Maximillans-Universit\u00e4t Munich, Munich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3621-4807","authenticated-orcid":false,"given":"Alessandro","family":"Pastore","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York City, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Haebe","sequence":"additional","affiliation":[{"name":"Department of Medicine III, University Hospital, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Department of Medicine III, University Hospital, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Katharina","family":"Zoellner","sequence":"additional","affiliation":[{"name":"Department of Medicine III, University Hospital, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[{"name":"Department of Medicine III, University Hospital, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Unterhalt","sequence":"additional","affiliation":[{"name":"Department of Medicine III, University Hospital, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Hoster","sequence":"additional","affiliation":[{"name":"Department of Medicine III, University Hospital, and"},{"name":"Institute for Medical Information Processing, Biometry and Epidemiology, Ludwig-Maximillans-Universit\u00e4t Munich, Munich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Hiddemann","sequence":"additional","affiliation":[{"name":"Department of Medicine III, University Hospital, and"},{"name":"German Cancer Consortium (DKTK), Munich, Germany; and"},{"name":"German Cancer Research Center (DKFZ), Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0987-7373","authenticated-orcid":false,"given":"Oliver","family":"Weigert","sequence":"additional","affiliation":[{"name":"Department of Medicine III, University Hospital, and"},{"name":"German Cancer Consortium (DKTK), Munich, Germany; and"},{"name":"German Cancer Research Center (DKFZ), Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2019,4,2]]},"reference":[{"issue":"6","key":"2020021108282606400_B1","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1182\/blood-2013-03-491514","article-title":"Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience","volume":"122","author":"Tan","year":"2013","journal-title":"Blood"},{"issue":"23","key":"2020021108282606400_B2","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"8","key":"2020021108282606400_B3","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood-2016-05-717355","article-title":"Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy","volume":"128","author":"Jurinovic","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2020021108282606400_B4","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"issue":"27","key":"2020021108282606400_B5","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"issue":"8","key":"2020021108282606400_B6","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.3324\/haematol.2018.187773","article-title":"Impact of age on genetics and treatment efficacy in follicular lymphoma","volume":"103","author":"Alig","year":"2018","journal-title":"Haematologica"},{"issue":"1","key":"2020021108282606400_B7","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2017-11-816405","article-title":"A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy","volume":"132","author":"Bachy","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2020021108282606400_B8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood-2018-05-847558","article-title":"The FLIPI nowadays: validation and modification","volume":"132","author":"Hoster","year":"2018","journal-title":"Blood"},{"issue":"12","key":"2020021108282606400_B9","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","article-title":"Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"issue":"11","key":"2020021108282606400_B10","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1182\/blood.V112.11.2599.2599","article-title":"Rituximab in combination with CHOP in patients with follicular lymphoma: analysis of treatment outcome of 552 patients treated in a randomized trial of the German Low Grade Lymphoma Study Group (GLSG) after a follow up of 58 months","volume":"112","author":"Buske","year":"2008","journal-title":"Blood"},{"issue":"9","key":"2020021108282606400_B11","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"issue":"4","key":"2020021108282606400_B12","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1470-2045(18)30102-5","article-title":"A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts","volume":"19","author":"Huet","year":"2018","journal-title":"Lancet Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/7\/1033\/1631584\/advances032136.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/7\/1033\/1631584\/advances032136.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T10:46:03Z","timestamp":1607165163000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/7\/1033\/247290\/Impact-of-age-on-clinical-risk-scores-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,2]]},"references-count":12,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,4,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019032136","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,2]]}}}